← Back to Screener
Sinovac Biotech, Ltd (SVA)
Price$6.47
Favorite Metrics
Price vs S&P 500 (26W)-1.60%
Price vs S&P 500 (4W)-2.08%
Market Capitalization$639.90M
All Metrics
P/CF (Annual)6.15x
Book Value / Share (Quarterly)$93.27
P/TBV (Annual)0.07x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-4.27%
Cash Flow / Share (Quarterly)$-4.06
Price vs S&P 500 (YTD)0.29%
Gross Margin (TTM)92.09%
Net Profit Margin (TTM)-29.06%
EPS (TTM)$-1.25
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-1.25
Revenue Growth (5Y)14.28%
EPS (Annual)$-1.00
ROI (Annual)-1.11%
Gross Margin (Annual)59.51%
Net Profit Margin (5Y Avg)13.77%
Cash / Share (Quarterly)$106.13
Revenue Growth QoQ (YoY)-13.33%
ROA (Last FY)-0.73%
Revenue Growth TTM (YoY)2.19%
EBITD / Share (TTM)$-1.24
ROE (5Y Avg)24.19%
Operating Margin (TTM)-103.87%
Cash Flow / Share (Annual)$-0.42
P/B Ratio0.07x
P/B Ratio (Quarterly)0.07x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-1.30x
Net Interest Coverage (TTM)1.00x
ROA (TTM)-0.94%
EV / EBITDA (TTM)-1.48x
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)10.31x
Quick Ratio (Quarterly)11.22x
3-Month Avg Trading Volume0.00M
52-Week Price Return0.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$93.26
P/S Ratio (Annual)1.43x
Asset Turnover (Annual)0.03x
52-Week High$6.47
Operating Margin (5Y Avg)-0.96%
EPS Excl Extra (Annual)$-1.00
CapEx CAGR (5Y)89.26%
Tangible BV CAGR (5Y)136.90%
26-Week Price Return0.00%
Quick Ratio (Annual)10.17x
13-Week Price Return0.00%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)11.39x
Enterprise Value$-10,947.096
Revenue / Share Growth (5Y)4.93%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)112.74%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.13x
Pretax Margin (Annual)-34.14%
Cash / Share (Annual)$112.64
3-Month Return Std Dev0.00%
Gross Margin (5Y Avg)76.36%
Net Income / Employee (TTM)$-0
ROE (Last FY)-1.15%
EPS Basic Excl Extra (Annual)$-1.00
P/FCF (TTM)7.01x
Receivables Turnover (TTM)1.08x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-1.25
Receivables Turnover (Annual)0.97x
ROI (TTM)-1.39%
P/S Ratio (TTM)1.49x
Pretax Margin (5Y Avg)25.90%
Revenue / Share (Annual)$4.50
Tangible BV / Share (Annual)$93.26
Price vs S&P 500 (52W)-36.95%
Year-to-Date Return0.00%
5-Day Price Return0.00%
EPS Normalized (Annual)$-1.00
ROA (5Y Avg)13.28%
Net Profit Margin (Annual)-22.29%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-5.38
EBITD / Share (Annual)$-0.96
Operating Margin (Annual)-134.52%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)23.84%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-1.25
P/TBV (Quarterly)0.07x
P/B Ratio (Annual)0.07x
Inventory Turnover (TTM)0.20x
Pretax Margin (TTM)-36.03%
Book Value / Share (Annual)$93.27
Price vs S&P 500 (13W)1.72%
Beta0.00x
P/FCF (Annual)0.04x
Revenue / Share (TTM)$4.31
ROE (TTM)-1.44%
52-Week Low$6.47
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SVASinovac Biotech, Ltd | 1.49x | 2.19% | 92.09% | — | $6.47 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Sinovac Biotech is a China-based biopharmaceutical company developing and commercializing vaccines for major infectious diseases. The company's portfolio includes vaccines for hepatitis A and B, hand-foot-mouth disease (EV71), influenza, coronavirus, pneumococcal disease, poliomyelitis, varicella, and mumps.